ACETAdicet Bio, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $9.05 · now $9.05 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, ACET has typically landed between $6.01 and $12.19 — a range of −33.6% to +34.7% from the issuance price $9.05.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

2,149 overlapping 1 month windows · 2018-01-26 – 2026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.7–56.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($9.05) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where ACET has typically landed a month from the 2026-09-16 close of $9.05 — the range is history, not a prediction.

$6.01worst · -33.6%$12.19best · +34.7%
  • now $9.05 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $8.74 (-3.4%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $7.48–$10.01
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $6.01–$12.19
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 2,149 windows spanning 2018-01-26 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2019-11-12−86.7%−88.5%+0.0%
2019-11-13−86.2%−87.3%+0.0%
2019-11-11−86.0%−88.0%+4.4%
3 best
2023-12-07+151.8%−3.6%+151.8%
2023-12-12+143.1%+0.0%+151.8%
2023-12-08+142.8%−4.3%+150.0%

2,149 overlapping windows · 2018-01-26 – 2026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~9 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
38%
+0.3%
n=8
Feb
56%
+0.3%
n=9
Mar
11%
−12.0%
n=9
Apr
56%
+2.2%
n=9
May
44%
+3.1%
n=9
Jun
22%
−6.7%
n=9
Jul
89%
+14.5%
n=9
Aug
22%
−8.3%
n=9
Sep
44%
−3.1%
n=9
Oct
25%
−6.4%
n=8
Nov
50%
−6.5%
n=8
Dec
50%
+5.5%
n=8

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$17$62026-04-08: 2 insider sales, $468K — ORBIMED ADVISORS LLC …2026-04-07: 2 insider sales, $207K — ORBIMED ADVISORS LLC …2026-02-20: 1 insider purchase, $543K — RA CAPITAL MANAGEMENT, L.P.2026-02-19: 1 insider purchase, $535K — RA CAPITAL MANAGEMENT, L.P.2026-02-18: 1 insider purchase, $525K — RA CAPITAL MANAGEMENT, L.P.2025-10-08: 2 insider purchases, $5.0M — ORBIMED ADVISORS LLC …2025-10: 2 open-market purchases, $5.0M2026-02: 3 open-market purchases, $1.6M2026-04: 4 open-market sales, $675K↑ buys↓ salesdirector ORBIMED ADVISORS LLC — Sale on 2026-04-08, filed 1 day after the tradedirector ORBIMED ADVISORS LLC — Sale on 2026-04-08, filed 1 day after the tradedirector ORBIMED ADVISORS LLC — Sale on 2026-04-07, filed 2 days after the tradedirector ORBIMED ADVISORS LLC — Sale on 2026-04-07, filed 2 days after the tradedirector RA CAPITAL MANAGEMENT, L.P. — Purchase on 2026-02-20, filed 52 days after the tradedirector RA CAPITAL MANAGEMENT, L.P. — Purchase on 2026-02-19, filed 53 days after the tradedirector RA CAPITAL MANAGEMENT, L.P. — Purchase on 2026-02-18, filed 54 days after the tradedirector ORBIMED ADVISORS LLC — Purchase on 2025-10-08, filed 2 days after the tradedirector ORBIMED ADVISORS LLC — Purchase on 2025-10-08, filed 2 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-04-08ORBIMED ADVISORS LLCdirectorSale40,416 @ $6.52$264K−100.0% of holding+18.8%not yet — horizon still open0Form 4 · filed 1 day after the trade
2026-04-08ORBIMED ADVISORS LLCdirectorSale32,523 @ $6.29$205K−100.0% of holding+18.8%not yet — horizon still open0Form 4 · filed 1 day after the trade
2026-04-07ORBIMED ADVISORS LLCdirectorSale29,319 @ $6.53$191K−45.6% of holding+21.7%not yet — horizon still open34,923Form 4 · filed 2 days after the trade
2026-04-07ORBIMED ADVISORS LLCdirectorSale2,400 @ $6.38$15K−6.9% of holding+21.7%not yet — horizon still open32,523Form 4 · filed 2 days after the trade
2026-02-20RA CAPITAL MANAGEMENT, L.P.directorPurchase74,751 @ $7.27$543K+6.7% of holding−2.0%+17.1%1,182,624Form 4 · filed 52 days after the trade
2026-02-19RA CAPITAL MANAGEMENT, L.P.directorPurchase74,268 @ $7.21$535K+7.2% of holding−2.0%+14.1%1,107,873Form 4 · filed 53 days after the trade
2026-02-18RA CAPITAL MANAGEMENT, L.P.directorPurchase74,577 @ $7.04$525K+7.8% of holding+4.0%+21.8%1,033,605Form 4 · filed 54 days after the trade
2025-10-08ORBIMED ADVISORS LLCdirectorPurchase3,500,000 @ $1.00$3.5M+353.4% of holding−26.7%−56.0%4,490,254Form 4 · filed 2 days after the trade
2025-10-08ORBIMED ADVISORS LLCdirectorPurchase1,500,000 @ $1.00$1.5M+19.9% of holding−26.7%−56.0%9,026,359Form 4 · filed 2 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

48 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-05Klickstein LloyddirectorAward / grant18,30018,300Form 4
2026-06-21DUBIN STEVEdirectorAward / grant4,2004,200Form 4
2026-06-21Chodakewitz JeffreydirectorAward / grant4,2004,200Form 4
2026-06-21Grissinger MichaeldirectorAward / grant4,2004,200Form 4
2026-06-21Sinclair AndrewdirectorAward / grant4,2004,200Form 4
2026-06-21Klickstein LloyddirectorAward / grant4,2004,200Form 4
2026-06-21Peng KatiedirectorAward / grant4,2004,200Form 4
2026-06-19Aftab BlakeofficerAward / grant55,00055,000Form 4
2026-06-19Schor ChendirectorAward / grant55,00055,000Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,0001,402,833Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,000932,624Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,0001,402,833Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,0001,402,833Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,000932,624Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,0001,402,833Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,000932,624Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,000932,624Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,0001,402,833Form 4
2026-04-27RA CAPITAL MANAGEMENT, L.P.directorOther acquisition250,000932,624Form 4
2026-03-25Healey DonofficerAward / grant43,36143,361Form 4
2026-03-25Maltzman Julia D.officerAward / grant72,55572,555Form 4
2026-03-25Schor ChendirectorAward / grant468,555468,555Form 4
2026-03-25Harvey Brian NicholasofficerAward / grant43,36143,361Form 4
2026-03-25Aftab BlakeofficerAward / grant72,55572,555Form 4
2026-01-24Schor ChendirectorWithheld for tax1,7556,820Form 4
2026-01-24Harvey Brian NicholasofficerWithheld for tax5465,145Form 4
2026-01-24Aftab BlakeofficerWithheld for tax5352,981Form 4
2026-01-24Healey DonofficerWithheld for tax5353,452Form 4
2025-06-11DUBIN STEVEdirectorAward / grant5,90022,700Form 4
2025-06-11DUBIN STEVEdirectorAward / grant26,40026,400Form 4
2025-06-11Sinclair AndrewdirectorAward / grant5,90017,700Form 4
2025-06-11Klickstein LloyddirectorAward / grant5,900108,566Form 4
2025-06-11Klickstein LloyddirectorAward / grant26,40026,400Form 4
2025-06-11Peng KatiedirectorAward / grant5,90011,800Form 4
2025-06-11Peng KatiedirectorAward / grant26,40026,400Form 4
2025-06-11Chodakewitz JeffreydirectorAward / grant5,90017,700Form 4
2025-06-11Chodakewitz JeffreydirectorAward / grant26,40026,400Form 4
2025-06-11Sinclair AndrewdirectorAward / grant26,40026,400Form 4
2025-04-17Grissinger MichaeldirectorAward / grant70,20070,200Form 4
2025-01-31Aftab BlakeofficerAward / grant275,000275,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.